Pharmaceutical Technology Editors

Jim Walter will take on the role of vice-president of operations for Catalent’s Oral and Specialty Delivery business.

The Brand Security Platform from ACG Inspection uses blockchain, the Internet of Things, and artificial intelligence technologies to track packages from manufacturer to consumer.

The program supports Emerson’s digital transformation initiative which encourages employees to learn at a faster pace through immersive experiences that enhance safety and overall operational performance.

A growing number of pharma executives see investment in machine learning and big data as a top priority, according to a 2020 GlobalData survey.

The company will showcase the syriQ BioPure syringe in a 2.25-mL format for autoinjectors at Pharmapack in Paris, France from Feb. 5¬¬–6, 2020.

The companies plan to provide characterization testing of container-closure systems for the biopharma industry.

Airnov announced on Feb. 5, 2020 at Pharmapack in Paris, France, that it will move forward as an independent company focused on desiccant and oxygen scavenging products for the pharmaceutical, diagnostic, and nutraceutical markets.

The two agencies are collaborating to support a robust biologics marketplace by taking steps to deter anti-competitive business practices.

FDA published draft guidance for applicants seeking licensure of a proposed biosimilar or proposed interchangeable biosimilar.

The new facility includes six classified environment rooms with space to expand.

Aimmune plans to introduce the antibody as an adjunctive treatment with its Characterized Oral Desensitized ImmunoTherapy programs to research treatment outcomes in patients with food allergies.

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

The knockout CHO K1 cell line will be used to support biotherapeutic R&D across a range of therapeutic indications.

West Pharmaceutical Services will be showcasing various new pharmaceutical containment and closure offerings at Pharmapack from Feb. 5–6 in Paris, France.

The vaccine is designed to provide active immunity against the influenza A (H5N1) strain and can be easily deployed in a pandemic event.

In replacing the retiring Paul Hegwood, Ricci Whitlow will oversee global clinical trial operations.

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended that Givlaari (givosiran) be granted marketing authorization in the European Union.

The UK BioIndustry Association (BIA) has issued a statement welcoming the publication of the Life Sciences 2030 Skills Strategy, a report setting out how the life sciences sector in the United Kingdom will develop future talent.

Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.

The partners will collaborate on developing scale-up chip-based technology to enable commercial-scale production of a third-generation DNA synthesis platform.

The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.

The company’s new Milliflex Oasis System provides enhanced result reliability, increased productivity, and advanced traceability.

Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.

WuXi’s R&D team will be developing and manufacturing 2019-nCoV-neutralizing antibodies at the company's four GMP facilities.

The company announced it will be unveiling a new name, Jones Healthcare Group, and a new corporate logo as it celebrates 100 years in the health and wellness markets.

J&J’s Janssen Pharmaceutical Companies seeks to develop a vaccine candidate against the novel coronavirus.

Clinical manufacturing of the therapy will take place at Lonza's Houston, TX, and Netherlands cGMP manufacturing sites.

The new 1800-m2 building houses more than 50 employees and features non-GMP laboratory space and a GMP analytical laboratory.

The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.

The agency has published seven guidance documents directed at the development and manufacture of gene therapies.